BioMarin Pharmaceutical (NASDAQ: BMRN) recently received a number of ratings updates from brokerages and research firms:
- 7/30/2024 – BioMarin Pharmaceutical was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 7/25/2024 – BioMarin Pharmaceutical had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $89.00 price target on the stock.
- 7/22/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
- 7/22/2024 – BioMarin Pharmaceutical was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 6/27/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Wells Fargo & Company from $110.00 to $115.00. They now have an “overweight” rating on the stock.
BioMarin Pharmaceutical Trading Up 0.4 %
BioMarin Pharmaceutical stock traded up $0.32 during trading hours on Tuesday, reaching $84.39. 1,022,542 shares of the company’s stock traded hands, compared to its average volume of 1,883,290. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.70 and a current ratio of 2.74. BioMarin Pharmaceutical Inc. has a fifty-two week low of $73.68 and a fifty-two week high of $99.56. The firm has a market capitalization of $16.02 billion, a price-to-earnings ratio of 78.87, a PEG ratio of 1.20 and a beta of 0.32. The firm’s 50 day moving average is $81.89 and its 200-day moving average is $85.31.
Insider Buying and Selling at BioMarin Pharmaceutical
In related news, EVP George Eric Davis sold 1,850 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $85.01, for a total value of $157,268.50. Following the sale, the executive vice president now directly owns 56,157 shares in the company, valued at approximately $4,773,906.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Brian Mueller sold 5,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $75.19, for a total transaction of $375,950.00. Following the completion of the sale, the chief financial officer now directly owns 72,159 shares of the company’s stock, valued at approximately $5,425,635.21. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP George Eric Davis sold 1,850 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $85.01, for a total value of $157,268.50. Following the sale, the executive vice president now directly owns 56,157 shares of the company’s stock, valued at $4,773,906.57. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,700 shares of company stock worth $5,209,352. Company insiders own 1.85% of the company’s stock.
Institutional Trading of BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Recommended Stories
- Five stocks we like better than BioMarin Pharmaceutical
- Stock Average Calculator
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Learn Technical Analysis Skills to Master the Stock Market
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Health Care Stocks Explained: Why You Might Want to Invest
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for BioMarin Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.